First Patient Dosed in Phase 1 Study of Attovia's ATTO-1310 for Chronic Pruritus

Image Credit: Pormezz - stock.adobe.com

Attovia Therapeutics announced today that the first patient has been dosed in its first-in-human, phase 1 clinical trial for ATTO-1310 for the treatment of chronic pruritus.¹

This novel therapeutic, designed to address pruritic conditions such as chronic pruritus of unknown origin (CPUO), is the first drug to utilize the company’s proprietary ATTOBODY platform.

Chronic pruritus, particularly conditions like CPUO, profoundly impacts the quality of life for millions globally.² Despite the debilitating nature of these conditions, no approved treatments currently exist for CPUO.¹

ATTO-1310 aims to fill this void with a therapeutic profile of rapid, deep, and sustained itch relief, a favorable safety profile, and subcutaneous administration.

ATTO-1310 is powered by Attovia’s ATTOBODY platform, a proprietary biologics technology designed to enhance potency and allow unparalleled engineering flexibility. The platform facilitates the development of half-life-extended molecules, requiring less frequent dosing.

The phase 1 trial (NCT06787586) is a double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of ATTO-1310. It will include both healthy adult volunteers and patients with pruritic conditions, progressing through single-ascending and multiple-ascending dose phases.³

Hubert Chen, MD, chief medical officer at Attovia, emphasized the significance of the trial.

"ATTO-1310 has the potential to provide life-changing relief to patients suffering from these diseases," Chen said in a news release.¹ "We are working with a group of international KOLs who have spent years advocating for the development of effective treatments for these patients, and who will help us drive progress in our clinical program. Advancement of ATTO-1310 into the clinic marks an important milestone for Attovia as we become a clinical-stage company delivering innovative therapies for patients with immune-mediated diseases."

While ATTO-1310 is the flagship product entering clinical trials, Attovia is advancing several additional ATTOBODY-based programs targeting immune-mediated diseases:¹

• ATTO-3712: A bispecific anti-IL13 x IL31 therapeutic, aimed at conditions like atopic dermatitis. This dual-action therapy seeks to address overlapping inflammatory pathways in skin disease.
• ATTO-004: A multispecific therapy under development for inflammatory bowel disease.
• Discovery Programs: Two early-stage programs are being explored for their potential in multi-disease applications.

References

1. Attovia Therapeutics announces first participant dosed in first-in-human phase 1 study of ATTO-1310, its novel half-life extended anti-IL-31 ATTOBODY for the treatment of chronic pruritus. News release. BioSpace. January 23, 2025. Accessed January 23, 2025. https://www.biospace.com/press-releases/attovia-therapeutics-announces-first-participant-dosed-in-first-in-human-phase-1-study-of-atto-1310-its-novel-half-life-extended-anti-il-31-attobody-for-the-treatment-of-chronic-pruritus
2. Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147(10):1153-1156. doi:10.1001/archdermatol.2011.178
3. ClinicalTrials.gov. A study to evaluate safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults and patients with pruritic disease. Updated January 23, 2025. Accessed January 23, 2025. https://clinicaltrials.gov/study/NCT06787586?term=NCT06787586&rank=1